This document provides an overview of Bayer's global operations and sales figures by region for 2009. It also summarizes the sales and R&D expenditures of Bayer's main divisions: CropScience, MaterialScience, and HealthCare. HealthCare had the highest sales at 15.9 billion Euros in 2009 and is divided into Pharmaceuticals, Consumer Care, Medical Care, Animal Health, and Diagnostic Imaging. The document highlights some of Bayer's major pipeline drugs and diagnostic imaging technologies in development.
The history of Clamoxyl and how Amoxicillin came in to picture. Amoxycillin, is an antibiotic useful for the treatment of a number of bacterial infections. It is the first line treatment, presented by me and my teammates
Drug food interactions in details - QAQussai Abbas
Drug interactions (DIs) represent an important and widely under recognized source of medication errors. Interactions between food and drugs may inadvertently reduce or increase the drug effect. Some commonly used herbs, fruits as well as alcohol may cause failure of the therapy up a point of to serious alterations of the patient’s health. The majority of clinically relevant food-drug interactions are caused by food induced changes in the bioavailability of the drug. Major side-effects of some diet (food) on drugs include alteration in absorption by fatty, high protein and fiber diets.
Underlying factors:
Classification of drug-food interactions:
Pharmacodynamic interactions
Pharmacokinetic interactions
I. Absorption interactions
II. Transport and distribution interactions
III. Metabolism interactions
IV. Excretion interactions
Grapefruit juice
Alcohol and Medication Interactions
Common Alcohol-Medication Interactions
Specific Alcohol-Medication Interactions
The history of Clamoxyl and how Amoxicillin came in to picture. Amoxycillin, is an antibiotic useful for the treatment of a number of bacterial infections. It is the first line treatment, presented by me and my teammates
Drug food interactions in details - QAQussai Abbas
Drug interactions (DIs) represent an important and widely under recognized source of medication errors. Interactions between food and drugs may inadvertently reduce or increase the drug effect. Some commonly used herbs, fruits as well as alcohol may cause failure of the therapy up a point of to serious alterations of the patient’s health. The majority of clinically relevant food-drug interactions are caused by food induced changes in the bioavailability of the drug. Major side-effects of some diet (food) on drugs include alteration in absorption by fatty, high protein and fiber diets.
Underlying factors:
Classification of drug-food interactions:
Pharmacodynamic interactions
Pharmacokinetic interactions
I. Absorption interactions
II. Transport and distribution interactions
III. Metabolism interactions
IV. Excretion interactions
Grapefruit juice
Alcohol and Medication Interactions
Common Alcohol-Medication Interactions
Specific Alcohol-Medication Interactions
Social impact of pharmaceutical industry. Sudipta Roy
Health is a critical challenge for society on basis of economic asset of people. Pharmaceutical industries and it's manufacturing products have been impacting health related issues for social and community development in major issues of reducing child and maternal mortality, slowing the spread of HIV/AIDS, malaria, tuberculosis, malnutrition of children promoting gender equality and empowerment.Here in this poster presentation, the fascinating role with its different manufacturing process for different types of dosage form of the pharmaceutical industry have been presenting for development of social care.
Bioavailability & Bioequivalence ppt, Objectives, Improving bioavailability, Assessment of bioavailability, Urinary excretion studies, Blood serum studies, in vitro drug dissolution testing, need for dissolution testing, in vitro drug dissolution testing models, Bioequivalence, Therapeutic equivalence, Types of bioequivalence studies, Pharmacokinetic studies, Methods to enhance dissolution rate.
Post-marketing drug safety surveillance refers to the monitoring of drugs once they reach the market after clinical trials through a process which evaluates drugs taken by individuals under a wide range of circumstances over an extended period.
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.
DRUG INTERACTIONS (MECHANISMS OF DRUG-DRUG INTERACTIONS)N Anusha
A Drug interaction is an interaction between a drug and some other substance, such as another drug or a certain type of food, which leads to interaction that could manifest as an increase or decrease in the effectiveness or an adverse reaction or a totally new side effect that is not seen with either drug alone that can be severe enough to alter the clinical outcome.
Every time a drug is administered with any other prescription medicine, OTC products, herbs or even food we expose ourselves to the risk of a potentially dangerous interaction.
Social impact of pharmaceutical industry. Sudipta Roy
Health is a critical challenge for society on basis of economic asset of people. Pharmaceutical industries and it's manufacturing products have been impacting health related issues for social and community development in major issues of reducing child and maternal mortality, slowing the spread of HIV/AIDS, malaria, tuberculosis, malnutrition of children promoting gender equality and empowerment.Here in this poster presentation, the fascinating role with its different manufacturing process for different types of dosage form of the pharmaceutical industry have been presenting for development of social care.
Bioavailability & Bioequivalence ppt, Objectives, Improving bioavailability, Assessment of bioavailability, Urinary excretion studies, Blood serum studies, in vitro drug dissolution testing, need for dissolution testing, in vitro drug dissolution testing models, Bioequivalence, Therapeutic equivalence, Types of bioequivalence studies, Pharmacokinetic studies, Methods to enhance dissolution rate.
Post-marketing drug safety surveillance refers to the monitoring of drugs once they reach the market after clinical trials through a process which evaluates drugs taken by individuals under a wide range of circumstances over an extended period.
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.
DRUG INTERACTIONS (MECHANISMS OF DRUG-DRUG INTERACTIONS)N Anusha
A Drug interaction is an interaction between a drug and some other substance, such as another drug or a certain type of food, which leads to interaction that could manifest as an increase or decrease in the effectiveness or an adverse reaction or a totally new side effect that is not seen with either drug alone that can be severe enough to alter the clinical outcome.
Every time a drug is administered with any other prescription medicine, OTC products, herbs or even food we expose ourselves to the risk of a potentially dangerous interaction.
This is the slide deck from the first lecture of the Consumer Health Informatics and Web 2.0 in Healthcare course at Nova Southeastern University. The course is taught by CCHIR faculty and guest lecturers. This deck is from the pharmacy version of the course.
CSCMP 2014: Bayer: Putting the S Back in S&OPAlyssaVallie
Balancing production efficiency and responsiveness to demand has never been more important or more challenging for companies with manufacturing-dominant cultures. Bayer Health Care shares their journey to S&OP excellence and how emphasizing the “S” in S&OP led to the successful redesign of its processes, overcoming ERP shortcomings to align market priorities with manufacturing capacity and extract the maximum competitive advantage from its supply chain.
The Value of Product-Specific Data for Marketing and Sales ROINutrasource
As regulatory requirements for foods and health products tighten across the world and product categories become increasingly competitive, more companies than ever are investing in research and development (R&D) to help their products stay novel, comply with regulations and stand out in the marketplace. Product-specific data is the common and trending theme that meets these objectives. In order to generate this data successfully and within budget, companies must ensure they are maximizing their return on investment (ROI) as it relates to product sales and marketing. This lecture will provide you with valuable information about the value of product-specific data for marketing and sales, and discuss specific strategies your company can use to maximize your return on this investment.
Yasmin Birth Control Pill is best contraception method. It Helps To Prevent Ovulation By Inhibiting The Release Of The Egg From The Ovary. It makes Difficulties For The Sperm To Reach The Uterus For The Fertilization.
For More Visit: http://www.abortionpill24.net/yasmin-pill-with-drospirenone-and-ethinylestradiol.html
Progynova Tablets for Treatment of Oestrogen DeficiencyThe Swiss Pharmacy
Progynova Tablets (Estradiol Valerate) is used as Hormone replacement therapy (HRT) for the treatment of signs and symptoms of oestrogen deficiency due to the menopause or after surgical removal of the ovaries.
Demand for biologics will exceed $100 billion in 2015, experiencing continuing strong growth following a decade of double-digit annual increases. Continued growth will be driven by dramatic shifts in production technology and expansion of targeted diseases, and challenged by the introduction of biosimilar products following patent expiry of major biologic products.
Weekly News Wrap-up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Wiekang Biotech Investor Presentation, June 2010GeoInvesting LLC
Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com
Biopharmaceuticals product segments analyzed in this study comprises Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and others. Therapeutic areas analyzed include Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and others. Biopharmaceuticals market, estimated at US$199.7 billion globally in 2013, is further projected to reach US$497.9 billion by 2020, growing at 13.5% CAGR between 2010 and 2020. Among different product segments, monoclonal antibodies (moAb) constitutes the largest product segment in the global biopharmaceuticals market accounting for an estimated share of 25.6% in 2013, equating to US$51.1 billion. In terms of therapeutic area, neurology applications is the largest market for global biopharmaceuticals with an estimated 2013 share of 28.2% valued at US$56.3 billion, and further expected reach a projected US$144.5 billion by 2020.
Biopharmaceuticals are medicinal drugs which are produced through biotechnology methods such as recombinant DNA techniques, fermentation, hybridoma techniques, and purification processes. Biopharmaceutical production involves the usage of biological sources, either live organisms or their active components. They are made up of proteins and nucleic acids and target specific diseases and patients groups. Biopharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments.
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Antimicrobial stewardship to prevent antimicrobial resistanceGovindRankawat1
India is among the nations with the highest burden of bacterial infections.
India is one of the largest consumers of antibiotics worldwide.
India carries one of the largest burdens of drug‑resistant pathogens worldwide.
Highest burden of multidrug‑resistant tuberculosis,
Alarmingly high resistance among Gram‑negative and Gram‑positive bacteria even to newer antimicrobials such as carbapenems.
NDM‑1 ( New Delhi Metallo Beta lactamase 1, an enzyme which inactivates majority of Beta lactam antibiotics including carbapenems) was reported in 2008
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
1. Bayer
Science for a Better Life
Benazir Ahmed Siddique, Product Executive, PMD
2. 2
Bayer World
E0504A
EUROPE
Sales 12 968 million
Employees 54 500
R&D expenses 2 080 million
Companies 156
ASIA/PACIFIC
Sales 5 712million
Employees 21 600
R&D expenses 131 million
Companies 57
LATIN AMERICA / AFRICA / MIDDLE EAST
Sales 4 783 million
Employees 16 000
R&D expenses 28 million
Companies 45
NORTH AMERICA
Sales 7 705 million
Employees 16 300
R&D expenses 507 million
Companies 156
3. 3
Bayer AG
JP Morgan 2011
Crop Protection
Environmental
Science
BioScience
Herbicides Professional products Vegetables
Fungicides Consumer products Agricultural Crops
Insecticides
Seed Treatment
Polyurethanes
Polycarbonates
Coating – Adhesives – Specialties
Consumer Care Pharmaceuticals Care
Animal Health Diabetes care
4. 4
Bayer Group Sales
31 168 million € in sales 2009
MaterialScience
25%
CropScience
22%
HealthCare
53%
10. 10
Animal Health
JP Morgan 2011
977million in sales 2009 (+1,5%)
More than 100 different health and care products
4th place in vetenary medicine market
Key Products
• ADVANTAGE against ticks for dogs and cats
• BAYTRIL to treat infectious diseases in livestock and companion animals
• DRONTAL to control endoparasites in pets
• BAYCOX to control coccidia problems in farm animals
12. Diabetes Care
JP Morgan
ASCENSIA
Blood glucose monitoring systems
Lancets
Individual test strips
No coding technology
MICROLET
Lancing
KETODIASTIX
Urinary bandage
A1cNow
Monitor to test glycated hemoglobin
13. Diabetes Care
JP Morgan
Bayer’s CONTOUR® USB meter
A new level of diabetes management
Share with your healthcare professional
Better manage your diabetes.
Bayer’s DIDGET
Plugs into a Nintendo DS
Encourage consistent testing with reward points
Getting a meter that’s reliable.
16. The Time of expansion
1978-1994
1972
Compagny renames Bayer AG
1989
Bayer acquieres Cooper Technicon:
It becomes one of the largest
suppliers of diagnostics systems and
reagents for clinical chemistry
Bayer acquires Miles Laboratories Inc. and
Sterling Winthrop‘s OTC to reestablishe
a presence in North America
The push for expansion as an
international health care
and chemicals group began.
16
18. FDA’s approval
Indications:
Treatment of primary
hypercholesterolemia and mixed
dyslipidemia
Raising HDL cholesterol
Post-marketing surveillance
• 52 deaths reported (rhabdomyolysis
renal failure)
• Risks if cerivastatin + gemfibrozil
highest dose (0.8 mg/day)
Withdrawn from the market worldwide in 2002
Cerivastatin Story
EMA’s approval: Mutual Recognition
Indications:
Hyperlipidemia (0.1 – 0.4mg/day)
Post-marketing surveillance
• Portugal requested that a full
assessment of the risk-benefit of
cerivastatin be carried out
• January 2002 the EMEA received a
fax from Bayer announcing that they
intended to withdraw all marketing
authorisations for cerivastatin
18
19. Bayer Health Care History
2004
Acquisition Roche ‘s OTC
2003
Cerivastatin withdrawal
19
20. 2004 : Acquisition of Roche’ OTC
3.6 billion Swiss francs = 3.7 billion Euros
Include : all assets of RCH + 5 pharmaceutical production factories
(Germany France Argentina Morocco Indonesia)
Roche sell its 50% stake in its joint venture with Bayer in the US
Analgesic, dermatological, gastrointestinal and nutritional products
Bayer’s Aspirin, Alka-Seltzer, Midol and One-A-Day
Roche’s Aleve, Bepanthen, Berocca, Flanax, Redoxon, Rennie, Supradyn
Top three non-prescription businesses worldwide
20
22. 22
Consumer Health sales
JP Morgan 2011
4 434million in sales
9M2010 (+4,3%)
801million of EBIT
9M2010 (+11,9%)
5 521 million € in sales
in 2009 (+2,7%)
3 divisions
24. 24
Animal Health 2010
JP Morgan 2011
865million in sales 9M2010 (+4,1%)
More than 100 different health and care products
4th place in vetenary medicine market
Key Products
• ADVANTAGE against ticks for dogs and cats
• BAYTRIL to treat infectious diseases in livestock and companion animals
• DRONTAL to control endoparasites in pets
• BAYCOX to control coccidia problems in farm animals
26. 26
Medical care
JP Morgan 2011
1 109million in sales 9M2010 (+3,2%)
2 divisions
Diabetes Care
Medrad
1 464million in sales in 2009 (+5,0%)
27. Diabetes Care
JP Morgan
ASCENSIA
Blood glucose monitoring systems
Lancets
Individual test strips
No coding technology
MICROLET
Lancing
KETODIASTIX
Urinary bandage
A1cNow
Monitor to test glycated hemoglobin
28. Diabetes Care
JP Morgan
Bayer’s CONTOUR® USB meter
A new level of diabetes management
Share with your healthcare professional
Better manage your diabetes.
Bayer’s DIDGET
Plugs into a Nintendo DS
Encourage consistent testing with reward points
Getting a meter that’s reliable.
33. Bayer Health Care History
2004
2005
Acquisition Roche ‘s OTC
Nexavar co developed with
Onyx Pharmaceuticals Inc
is approved by FDA
2003
Cerivastatin withdrawal
2006
Acquisition of Schering AG
33
34. The merger Bayer – Schering AG
March 13,
2006
• Merck Darmstadt announced a €14.6 bn bid for
Schering AG
March 23,
2006
• Merck's takeover bid was surpassed by Bayer's €16.5 bn
white-knight bid for Schering
June 12,
2006
• Merck KGaA disrupts takeover
June 16,
2006
• Bayer finally bought the majority of shares, over 90%
34
37. Since 1970, patients and physicians
were full enthousiam about hormone
therapy replacement
Prevention of osteoporosis
Prevention cardiovascular disease
Prevention skin ageing
Prevention Alzheimer disease
1997 : mammary risk in Lancet
1998 : HERS Study
they have doubts on cardiovascular
benefits
AFSSAPS limited indications
Hormone replacement therapy Scandal
July 2002: Women Health Initiative Study
Increasing mammary and
cardiovascular risks
August 2003 Million Women Study
Increasing breast cancer risk
whatever HRT
6 products were concerned
ANGELIQ CLIMENE
AVADENE CLIMODIENE
CLIMARA PROGYNOVA
40. Since 2007: Life cycle management,
Inlicensing and Cooperation agreements
2007
The best year
↗ 11.8% CA
↗ 21.4% EBITDA
Expansion in the pharmaceuticals market Brazil,
Mexico, South Korea, India, Turkey and Russia
2008
Acquisition OTC’s Topsun Science Tecgnology Qidong
Gaitianli Pharmaceutical in China (cough and cold)
Acquisition OTC’s Sagmel Inc in Eastern Europe
Development of Medical Care Division
40
41. 2009
Since 2007: Life cycle management,
Inlicensing and Cooperation agreements
Continue to strengthening Consumer Health:
Licencing agrement with Astra Zeneca: marketing of OTC’s omeprazole
April, 29 2009
Continue business expansion in emerging markets
41
43. 43
Bayer HealthCare 2009
JP Morgan 2011
15 988million in sales in 2009
1 847million in R&D
67%of all R&D expenditures by Bayer Group
17,6% of turnover
3 R&D sites
53 400employees
49. 50
E0504A
JP Morgan 2011
Xarelto Inhibits the Blood-clotting Process at
Pivotal Stage
Anticoagulant drug : inhibits the coagulation cascade
Current treatement options have limitations :
Heparin
-> parenteral administration
Vitamin K antagonists (e.g. Warfarin)
-> narrow therapeutic window,
-> slow onset of action,
-> unpredictable pharmacology
Once-daily oral dosing
No dose adjustment for age, sex or body weight
No requirement for routine coagulation monitoring
51. 52
E0504A
JP Morgan 2011
http://www.press.bayer.com/baynews/baynews.nsf/id/E308276CDC5F62FEC125771C001F6F32
Nexavar
Indications:
1. Treatment of hepatocellular carcinoma. (HCC)
2. Treatment of patients with advanced renal cell carcinoma (RCC) who have
failed prior interferon-alpha or interleukin-2 based therapy or are considered
unsuitable for such therapy
Nexavar targets both the tumor cell and tumor vasculature.
It targets kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3
and RET.
This medicine has an "orphan designation" (used to treat no more than five in 10,000
people in the European Union)
52. 53
E0504A
JP Morgan 2011 - http://www.medicalnewstoday.com/articles/164359.php
Building Blocks of Bayer’s Oncology Pipeline
Nexavar continues to be evaluated as a single agent
or combination treatment in a wide range of cancers
53. 54
E0504A
JP Morgan 2011 - http://gistsupport.medshelf.org/Regorafenib - http://www.dddmag.com/news-Regorafenib-Receives-Orphan-Drug-Status-2711.aspx
http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_O/threadview?m=tm&bn=13414&tid=52299&mid=52395&tof=10&rt=2&frt=2&off=1
Regorafenib – A new Tyrosine Kinase Inhibitor
Regorafenib is an orally active multikinase inhibitor
(VEGF-R… : angiogenesis)
Regorafenib may have additional anti-tumor targets that Nexavar doesn't have...by
switching out a single hydrogen atom for a flourine atom.
Regorafenib is ALMOST (but not quite) identical to Nexavar.
Regorafenib blocks another component of angiogenesis : TIE2
which along with VEGFR also supports angiogenesis.
Regorafenib
Regorafenib works better than Nexavar in renal cell carcinoma.
February 07, 2011 : Regorafenib Receives Orphan Drug Status for the
treatment of patients with gastrointestinal stromal tumors (GIST) by the FDA.
55. 56
E0504A
http://www.mult-sclerosis.org/Betaseron.html - http://www.kogenatefs.com/webapp/
Betaferon® - Kogenate®
Kogenate® FS is a recombinant factor VIII
product indicated for the treatment of
hemophilia A.
Betaseron®, known as Betaferon® in
Europe, was manufactured by Schering
and its US associate Berlex.
It is a form of beta interferon
(interferon beta, IFN-b) used to modify
the course of multiple sclerosis.
58. 59
E0504A
JP Morgan 2011 - http://retinaeyedoctor.com/2010/11/vegf-trap-for-macular-degeneration/ - http://www.retinalphysician.com/article.aspx?article=104951
VEGF Trap-Eye
The VEGF Trap is VEGF Trap-Eye is a recombinant fusion
protein consisting of portions of human VEGF-R 1 and 2
extracellular domains, fused to the Fc portion of human
IgG1
It is specifically designed to bind all forms of Vascular
Endothelial Growth Factor-A (VEGF-A) and Placental
Growth Factor (PLGF) proteins that are involved in the
abnormal growth of new blood vessels.
VEGF Trap-Eye (Aflibercept) for the treatment of Macular
Degeneration by local administration.
The sponsoring pharmaceutical companies, Bayer and
, just reported favorable results in their own
Phase III studies.
64. 65
E0504A
JP Morgan 2010
Bayer’s Pharma Business is Underexposed to the
U.S. Market…
The US pharma market represents ~40%
of the global market
23% of Bayer’s global pharma sales
generated in the US (2008)
Portfolio focuses on specialty pharma and
biologicals :
Oncology
Hemophilia
Women’s Healthcare
Multiple Sclerosis
69. SWOT Bayer: Our opinion
Strenghts
Three differents entities
A banlanced and strong Pipeline
Specialty medicines
Separated OTC
Well-known brand names
Weaknesses
Material Science
US market
Opportunities
Biotech investment
Target population of Xarelto
Emerging markets
Threats
Risk of OPA in long term
New oral treatments for MS
70
70. Thanks for your attention
Stéphanie DURLIN, Marie FOURCROY, Orane LISIECKI